Satori Pharmaceuticals, a US-based drugs company whose logos is derived from the Japanese for Buddhist enlightenment, has raised a third of its planned $21m round from three investors, according to its regulatory filing.
The $7m initial close was first reported by news provider Citybizlist. Satori raised $22m in its series B round in early 2009 from venture capital firms InterWest Partners, New Enterprise Associates and Prospect Venture Partners and has Steven Holtzman from Nasdaq-listed Infinity Pharmaceuticals and Edward Mathers, previously from MedImmune, on its board.